Experimental study showed that exendin-4, one of the GLP-1 receptor agonists, significantly reduces tumor volume when LNCap cells are transplanted into thymopathic mice.[11] This is due to the fact that GLP-1R mRNA was abundantly expressed in LNCap cells, and exendin-4 reduces the proliferation of prostate cancer cells through the activation of the GLP-1 receptor, thereby inhibiting ERK-MAPK. Here, GLP1R is linked to prostate carcinoma.